Ribociclib Improves Survival in Advanced Breast Cancer - Cancer Currents Blog National Cancer Institute sent this bulletin at 10/06/2021 10:33 AM EDT The latest from the NCI Cancer Currents blog Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer 10/06/2021 In a large clinical trial, women with HR-positive, HER2-negative metastatic breast cancer treated with ribociclib (Kisqali) and letrozole (Femara) as their initial treatment lived approximately 1 year longer than women treated with letrozole only.
